Dimethyl fumarate: targeting glycolysis to treat MS

被引：20
|
作者：
Angiari, Stefano [1 ]
O'Neill, Luke A. [1 ]
机构：
[1] Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin 2, Ireland
来源：
CELL RESEARCH | 2018年 / 28卷 / 06期
基金：
英国惠康基金;
关键词：
D O I：
10.1038/s41422-018-0045-3
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Dimethyl fumarate (DMF) is an immunomodulatory drug used in patients with multiple sclerosis (MS) and psoriasis. Kornberg and colleagues shed new light on DMF activity, demonstrating that it blocks immune cell activation through inhibition of glycolysis via post-transcriptional modification of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which confirms the pro-inflammatory role of glycolysis and points to potential new targets to treat inflammatory diseases such as MS.
引用
收藏
页码：613 / 615
页数：3
相关论文
共 50 条
  • [31] Delayed-release dimethyl fumarate safe to use in MS patients
    Reactions Weekly, 2018, 1714 (1) : 6 - 6
  • [32] Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis
    Toyama, Tetsuo
    Looney, Agnieszka P.
    Baker, Brendon M.
    Stawski, Lukasz
    Haines, Paul
    Simms, Robert
    Szymaniak, Aleksander D.
    Varelas, Xaralabos
    Trojanowska, Maria
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (01) : 78 - 88
  • [33] Adherence, cognition and behavioral outcomes in Multiple Sclerosis (MS) patients on dimethyl fumarate-12-month results of a longitudinal registry study in German MS practices (TREAT)
    Scholl, S.
    Thaler, L.
    Rossnagel, F.
    Schlegel, S.
    Braisch, U.
    Lehr, L.
    Sedlmeier, R.
    Schmid, B.
    Freudensprung, U.
    Muche, R.
    Bergmann, A.
    Schreiber, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 408 - 408
  • [34] Lorcaserin, dimethyl fumarate, and bedaquiline fumarate
    Hussar, Daniel A.
    Polyak, Georgiy
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2013, 53 (03) : 328 - 334
  • [35] Targeting Epstein-Barr virus to treat MS
    Chitnis, Tanuja
    Weiner, Howard L.
    MED, 2022, 3 (03): : 159 - 161
  • [36] Quantitative spinal cord MRI as a biomarker of treatment response to dimethyl fumarate in MS
    Kang, H.
    Glaister, J.
    Guenette, M.
    Suthiphosuwan, S.
    Bharatha, A.
    Oh, J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 430 - 430
  • [37] An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis
    Lorefice, L.
    Fenu, G.
    Cabras, F.
    Frau, J.
    Coghe, G. C.
    Loi, L.
    Marrosu, M. G.
    Cocco, E.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 7 : 65 - 67
  • [38] Stability of longitudinal DTI metrics in MS with treatment of injectables, fingolimod and dimethyl fumarate
    Alshehri, Abdulaziz
    Al-iedani, Oun
    Koussis, Nikitas
    Khormi, Ibrahim
    Lea, Rodney
    Lechner-Scott, Jeannette
    Ramadan, Saadallah
    NEURORADIOLOGY JOURNAL, 2023, 36 (04): : 388 - 396
  • [39] Longitudinal Variations of Neuro Metabolites and MS Fatigue in Patients Treated with Dimethyl Fumarate
    Arm, Jameen
    Ribbons, Karen
    Lea, Rod
    Ramadan, Saadallah
    Lechner-Scott, Jeannette
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 394 - 394
  • [40] Detecting Dimethyl Fumarate Content in Leather and Textile Products by GC-MS
    Fu, Kejie
    Zhang, Chi
    Zhang, Hui
    Zhou, Wenlong
    JOURNAL OF THE SOCIETY OF LEATHER TECHNOLOGISTS AND CHEMISTS, 2014, 98 (02): : 76 - 81
12345